Clinical Trials

Please contact your Abramson Cancer Center Oncologist about enrollment into a trial. If you do not have an Abramson Cancer Center Oncologist, please contact our Pancreas Nurse Navigator Patricia Gambino at 215-615-0537 or Patricia.Gambino@uphs.upenn.edu to make an appointment with one of our Oncologists to discuss clinical trials. 

Adjuvant
Trial # Trial Type of therapy Description PI/Contact
UPCC 04218 Immunotherapy Adjuvant Pilot study of mature dendritic cell vaccination against mutated KRAS in patients with resectable pancreatic cancer (KRAS dendritic cell vaccine with cyclophosphamide lymphodepletion) Adham Bear/Mark O'Hara, MD
EA2192 (APOLLO) Olaparib Adjuvant Randomized, double blind study of olaparib vsplacebo following adjuvant platinum based chemotherapy in patients with resected pancreatic adenocarcinoma and a pathogenic BRCA1, BRCA2 or PALB2 mutation

Mary Oladjei/Kim A. Reiss, MA

Research RN: Nancy Dinubile

 

Localized, Resectable
Trial # Trial Type of therapy Description PI/Contact
UPC 22217 Gemcitabine/cisplatin/nab-paclitaxel/nivolumab with or without vitamin D Neo-adjuvant -resectable A randomized pilot study of perioperative nivolumab and paricalcitol to target the microenvironment in resectable epithelial subtype pancreatic cancer. Alyssa Donze/Peter O’Dwyer, MD

 

Localized, Unresectable

Trial # Trial Type of therapy Description PI/Contact
UPCC 32213 Radiation & nab®-Paclitaxel Locally advanced A phase I dual dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer Alexis Giron/Edgar Ben-Josef, MD

 

Metastatic trials — First Line (Initial treatment for newly metastatic diagnosis)
Trial # Trial Type of therapy Description PI/Contact
UPCC 07220 AB680 (CD73 inhibitor), AB122 (PD-1 inhibitor) 1st line metastatic Phase I study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies (gem/abraxane, AB680 (CD73 inhibitor that decreases adenosine), AB122 (anti-PD-L1)) Natalia Izgur/Mark O'Hara, MD
UPCC 21219 Various drugs 1st line metastatic Precision Promise (randomized 70% to GA + pamrevlumab or 30% mFFX or GA); Creon available to all patients Alyssa Donze/Gregory L. Beatty, MD, PhD
UPCC 06221 Gemcitabine, nab-paclitaxel, ipilimumab and HCQ 1st line metastatic

REVOLUTION

cohort B – gemcitabine, nab-paclitaxel, ipilimumab and HCQ

cohort C - gemcitabine, nab-paclitaxel, ipilimumab, CD40 oncolytic virus

Mark O'Hara, MD
UPCC 23220 Gemcitabine, nab-paclitaxel, paricalcitol 1st line metastatic Phase 2 study to evaluate Gem/Abraxane in combination with paricalcitol (Vit D). Randomization to 1) paricalcitol i.v.weekly, 2) paricalcitol p.o., or 3) oral placebo

Alyssa Donze/

Tom Karasic, MD

 

Metastatic Trials — Second Line
Trial # Trial Type of therapy Description PI/Contact
UPC 21219 Various drugs 1st & 2nd line - Metastatic Pancreatic Cancer Precision Promise (randomized 70% SM88 or GA + pamrevlumab or 30% mFFX or GA); Creon available to all patients Alyssa Donze/Gregory L. Beatty, MD, PhD
UPCC 03821 Modified human CAR T cells 2nd line - Metastatic Pancreatic Cancer Phase I study of human CAR modified T cells (huCART-meso) administered in combination with VCN-01 (hyaluronidase-secreting oncolytic adenovirus) in PDAC and ovarian cancers. ECOG 0 patients preferred Kim Shea/Mark O'Hara, MD

 

Metastatic Maintenance
Trial # Trial Type of therapy Description PI/Contact
UPCC 15222

Immune therapy

1st line - Maintenance Metastatic Phase 1b study of soluble beta glucan (odetiglucan) in combination with CD40 agonist (CDX-1140) Natalia Izgur/Max Wattenberg/Mark O'Hara

SIV S2001

PARP inhibitor 1st line - Maintenance Metastatic A randomized Phase II clinical trial of Olaparib + Pembrolizumab vs. Olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with Germline BRCA1 or BRCA2 mutations Kim Reiss Binder, MA

 

Biomarker Trials
Trial # Trial Type of therapy Description PI/Contact
UPCC 22210 Pancreatic Tissue Acquisition No Therapy Protocol to permit the acquisition of samples of tumor and normal tissue for biological endpoints in pancreatic cancer Peter O`Dwyer, MD
UPCC 02215 Circulating Tumor Material No Therapy Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases and Control Subjects Peter O`Dwyer, MD

 

Please contact your Abramson Cancer Center Oncologist about enrollment into a trial. If you do not have an Abramson Cancer Center Oncologist, please contact our Pancreas Nurse Navigator Patricia Gambino at 215-615-0537 or patricia.gambino@uphs.upenn.edu to make an appointment with one to discuss clinical trials.

Please note that openings for clinical trials are highly variable. Consequently, at any given time there may not be open slots for the trials shown here. Conversely, slots may be available for clinical trials that have not yet been listed on this page. To determine whether a clinical trial may be appropriate for you, please contact your Abramson Cancer Center Oncologist at 1-800-789-7366.